CTNNB1, AXIN1 and APC expression analysis of different medulloblastoma variants

Clinics

Volumn 68, Issue 2, 2013, Pages 167-172

  da Silva, Roseli ^a   Marie, Suely K N ^a   Uno, Miyuki ^a   Matushita, Hamilton ^a   Wakamatsu, Alda ^a   Rosemberg, Sergio ^a   Oba Shinjo, Sueli M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

catenin; Gene expression; Immunohistochemistry; Medulloblastoma; Wnt pathway

Indexed keywords

APC PROTEIN; AXIN; AXIN1 PROTEIN, HUMAN; BETA CATENIN; CTNNB1 PROTEIN, HUMAN;

ADULT; ARTICLE; CEREBELLUM TUMOR; CHI SQUARE DISTRIBUTION; CHILD; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; MALE; MEDULLOBLASTOMA; METABOLISM; NONPARAMETRIC TEST; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; WNT SIGNALING PATHWAY;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ADULT; AXIN PROTEIN; BETA CATENIN; CEREBELLAR NEOPLASMS; CHI-SQUARE DISTRIBUTION; CHILD; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMANS; MALE; MEDULLOBLASTOMA; REAL-TIME POLYMERASE CHAIN REACTION; STATISTICS, NONPARAMETRIC; WNT SIGNALING PATHWAY;

EID: 84875652172     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2013(02)OA08     Document Type: Article

References (49)

1. Giangaspero F, Eberhart CG, Haapasala H, Pietsch T, Wiestler OD, Ellison DW. Medulloblastoma. In WHO classification of tumors of the central nervous system Eds DN Louis, H Ohgaki, OD Wiestler, WK Cavenee, IARC, France, 2007:132-40.
2. Giordana MT, Schiffer P, Schiffer D. Prognostic factors in medulloblastoma. Child9s Nerv Syst. 1998;14(6):256-62, http://dx.doi.org/10.1007/s003810050221.
3. Louis ND, Ohgaki H, Wiestler DO, Cavenee KW, Burger CP, Jouvet A, et al. The 2007 WHO Classification of tumors of the Central Nervous System. Acta Neuropathol. 2007;114(2):97-109, http://dx.doi.org/10. 1007/s00401-007-0243-4.
4. Gulino A, Arcella A, Giangaspero F. Pathological and molecular heterogeneity of medulloblastoma. Curr Opin Oncol. 2008;20(6):668-75, http://dx.doi.org/10.1097/CCO.0b013e32831369f4.
5. Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, Lau CC, et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol. 2006;24(12):1924-31, http://dx. doi.org/10.1200/JCO.2005.04.4974.
6. Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P, et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One. 2008;3(8):e3088, http://dx.doi.org/10.1371/journal. pone.0003088.
7. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, Bouffet E, Clifford SC, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. 2011;29(11):1408-14, http://dx.doi.org/10.1200/JCO.2009.27.4324.
8. Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol. 2011;29(11):1424-30, http://dx.doi.org/10.1200/JCO.2010.28.5148.
9. Kool M, Korshunov A, Remke M, Jones DT, Schlanstein M, Northcott PA, et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol. 2012;123(4):473-84, http://dx.doi.org/10.1007/s00401-012-0958-8.
10. Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012;123(4):465-72, http://dx.doi.org/10.1007/s00401-011-0922-z.
11. Clifford SC, Lusher ME, Lindsey JC, Langdon JA, Gilbertson RJ, Straughton D, et al. Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle. 2006;5(22):2666-70, http://dx.doi.org/10.4161/cc.5.22.3446.
12. Wodar, A & Nusse, R. Mechanisms of Wnt signaling in development. Annu. Rev. Cell Dev Biol. 1998;14:59-88, http://dx.doi.org/10.1146/annurev.cellbio.14.1.59.
13. Kikuchi A. Tumor formation by genetic mutations in the components of the Wnt signaling pathway. Cancer Sci. 2003;94(3):225-9, http://dx.doi. org/10.1111/j.1349-7006.2003.tb01424.x.
14. Morin PJ. Beta-catenin signaling and cancer. Bioessays. 1999;21(12):1021-30, http://dx.doi.org/10.1002/(SICI)1521-1878(199912)22:1,1021::AIDBIES6.3.0. CO;2-P.
15. Wong CM, Fan ST, Ng IO. Beta-catenin mutation and over expression in hepatocellular carcinoma. Cancer. 2001;92(1):136-45, http://dx.doi.org/10.1002/1097-0142(20010701)92:1,136::AID-CNCR1301.3.0.CO;2-R.
16. Cui J, Zhou X, Liu Y, Tang Z, Romeih M. Wnt signaling in hepatocellular carcinoma: analysis of mutation and expression of beta-catenin, T-cell factor-4 and glycogen synthase kinase 3-beta genes. J Gastroenterol Hepatol. 2003;18(3):280-7, http://dx.doi.org/10.1046/j.1440-1746.2003. 02973.x.
17. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1997;275(5307):1787-90, http://dx.doi.org/10.1126/science.275.5307.1787.
18. Peifer M. Beta-catenin as oncogene: the smoking gun. Science. 1997;275(5307):1752-3, http://dx.doi.org/10.1126/science.275.5307.1752.
19. Zhurinsky J, Sctutman M, Bem-Ze'ev A. Plakoglobin and b-catenin: protein interactions, regulation and biological roles. J Cell Sci. 2000;113 (Pt 18):3127-39.
20. Howell BW, Hertz J. The LDL receptor gene family: signalling functions during development. Curr Opin Neurobiol. 2001;11(1):74-81, http://dx. doi.org/10.1016/S0959-4388(00)00176-8.
21. Polaskis P. Wnt signaling and cancer. Genes Dev. 2007;14:1837-51.
22. Miller K, Auld J, Jessup E, Rhodes A, Ashton-Key M. Antigen unmasking in formalin-fixed routinely processed paraffin wasembedded section by pressure cooking: A comparison with microwave oven heating and traditional methods. Advances Anat Pathol. 1995;2:60-4, http://dx.doi.org/10.1097/00125480-199501000-00044.
23. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabed antibody (PAP) procedure. J Histochem Cytochem. 1981;29(4):577-80, http://dx.doi.org/10.1177/29.4.6166661.
24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T) Method. Methods. 2001;25(4):402-8, http://dx.doi.org/10.1006/meth.2001.1262.
25. Eberhart CG, Tihan T, Burger PC. Nuclear localization and mutation of beta-catenin in medulloblastomas. J Neuropathol Exp Neurol. 2000;59(4):333-37.
26. Marino S. Medulloblastoma: developmental mechanisms out of control. Trends Mol Med. 2005;11(1):17-22, http://dx.doi.org/10.1016/j.molmed. 2004.11.008.
27. Reya T, Clevers H. Wnt signaling in stem cells and cancer. Nature 2005; 434:843-50, http://dx.doi.org/10.1038/nature03319.
28. Min HS, Lee YJ, Park K, Cho BK, Park SH. Medulloblastoma: histopathologic and molecular markers of anaplasia and biologic behavior. Acta Neuropathol. 2006;112(1):13-20, http://dx.doi.org/10. 1007/s00401-006-0073-9.
29. Yokota N, Nishizawa S, Ohta S, Date H, Sugimura H, Namba H, et al. Role of Wnt pathway in medulloblastoma oncogenesis. Int J Cancer. 2002;101(2):198-201.
30. Ellison DW, Onilude OE, Lindsey JC, Lusher ME, Weston CL, Taylor RE, et al. b-catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer study group brain tumour Committee. J Clin Oncol. 2005;23(31):7951-7, http://dx.doi. org/10.1200/JCO.2005.01.5479.
31. Ellison DW, Kocak M, Dalton J, Megahed H, Lusher ME, Ryan SL, et al. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clinic Oncol. 2011;29(11):1400-7, http://dx.doi.org/10.1200/JCO.2010. 30.2810.
32. Schroeder JA, Adriance MC, McConnell EJ, Thompson MC, Pockaj B, Gendler SJ. ErbB-beta-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu transgenic carcinomas. J Biol Chem. 2002;277(25):22692-8, http://dx.doi.org/10.1074/jbc.M201975200.
33. Meng X, Poon R, Zhang X, Cheah A, Ding Q, Hui CC, Alman B. Suppressor of fused negatively regulates beta-catenin signaling. J Biol Chem. 2001;276(43):40113-9, http://dx.doi.org/10.1074/jbc.M105317200.
34. Taya S, Yamamoto T, Kanai-Azuma M, Wood SA, Kaibuchi K. The deubiquitinating enzyme Fam interacts with and stabilizes beta-catenin. Genes Cells. 1999;4(12):757-67, http://dx.doi.org/10.1046/j.1365-2443. 1999.00297.x.
35. Pantaleon M, Kanai-Azuma M, Mattick JS, Kaibuchi K, Kaye PL, Wood SA. FAM deubiquitylating enzyme is essential for preimplantation mouse embryo development. Mech Dev. 2001;109(2):151-60, http://dx. doi.org/10.1016/S0925-4773(01)00551-2.
36. Cong F, Varmus H. Nuclear-cytoplasmic shuttling of axin regulates subcellular localization of beta-catenin. Proc Natl Acad Sci USA. 2004;101(9):2882-7, http://dx.doi.org/10.1073/pnas.0307344101.
37. Henderson BR. Nuclear-cytoplasmic shuttling of APC regulates betacatenin subcellular localization and turnover. Nat Cell Biol. 2000;2(9):653-60, http://dx.doi.org/10.1038/35023605.
38. Huang L, Chen D, Liu D, Yin L, Kharbanda S, Kufe D. Muc1 oncoprotein blocks glycogen synthase kinase 3b-mediated phosphorylation and degradation of b-catenin. Cancer Res. 2005;65(22):10413-22, http://dx. doi.org/10.1158/0008-5472.CAN-05-2474.
39. Rogers HA, Miller S, Lowe J, Brundler MA, Coyle B, Grundy RG. An investigation of WNT pathway activation and association with survival in central nervous system primitive neuroectodermal tumours (CNS PNET). Br J Cancer. 2009;100(8):1292-302, http://dx.doi.org/10.1038/sj. bjc.6604979.
40. Pizem J, Popovic M, Cö r A. Expression of Gli1 and PARP1 in medulloblastoma: an immunohistochemical study of 65 cases. J Neurooncol. 2010;103(3):459-67.
41. Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC, et al. The genetic landscape of the childhood cancer medulloblastoma. Science. 2011;331(6016):435-9, http://dx.doi.org/10.1126/science.1198056.
42. Rosin-Arbesfeld R, Townsley F, Bienz M. The APC tumour suppressor has a nuclear export function. Nature. 2000;406(6799):1009-12.
43. Wechsler-Reya RJ, Scott MP. Expansion of CNS precursor pools: a new role for Sonic Hedgehog. Neuron. 1999;22(1):2-3.
44. Huang H, Mahler-Araujo BM, Sankila A, Chimelli L, Yonekawa Y, Kleihues P, Ohgaki HV. APC mutations in sporadic medulloblastomas. Am J Pathol. 2000;156(2):433-7.
45. Baeza N, Masuoka J, Kleihues P, Ohgaki H. AXIN1 mutations but not deletions in cerebellar medulloblastomas. Oncogene. 2003;22(4):632-6, http://dx.doi.org/10.1038/sj.onc.1206156.
46. Salaroli R, Russo A, Ceccarelli C, Mina GD, Arcella A, Martinelli GN, et al. Intracellular distribution of beta-catenin in human medulloblastoma cell lines with different degree of neuronal differentiation. Ultrastruct Pathol. 2007;31(1):33-44, http://dx.doi.org/10.1080/01913120 601169501.
47. Kongkham PN, Northcott PA, Croul SE, Smith CA, Taylor MD, Rutka JT. The SFRP family of WNT inhibitors function as novel tumor suppressor genes epigenetically silenced in medulloblastoma. Oncogene. 2010;29 (20):3017-24, http://dx.doi.org/10.1038/onc.2010.32.
48. Bovolenta P, Esteve P, Ruiz JM, Cisneros E, Lopez-Rios J. Beyond Wnt inhibition: new functions of secreted Frizzled-related proteins in development and disease. J Cell Sci. 2008;121(Pt 6):737-46, http://dx. doi.org/10.1242/jcs.026096.
49. Fattet S, Haberler C, Legoix P, Varlet P, Lellouch-Tubiana A, Lair S, Manie E, et al. Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical Characteristics. J Pathol. 2009;218(1):86-94, http://dx.doi.org/10.1002/path.2514.